Get the Stockscreener App
0.7746
7.03%
-0.0586
After Hours:
.77
-0.0046
-0.59%
Standard Biotools Inc stock is traded at $0.7746, with a volume of 1.61M.
It is down -7.03% in the last 24 hours and up +5.50% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
See More
Previous Close:
$0.8332
Open:
$0.8305
24h Volume:
1.61M
Relative Volume:
0.47
Market Cap:
$303.23M
Revenue:
$86.26M
Net Income/Loss:
$-50.08M
P/E Ratio:
-3.1629
EPS:
-0.2449
Net Cash Flow:
$-94.48M
1W Performance:
-8.87%
1M Performance:
+5.50%
6M Performance:
-47.66%
1Y Performance:
-44.67%
1-Day Range:
$0.7675
$0.852
1-Week Range:
$0.7675
$0.8999
52-Week Range:
$0.7029
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.7746 | 326.17M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Form 4 Standard Biotools Inc For: 27 July By Investing.com - Investing.com Canada
Standard BioTools Inc. (LAB) CFO share withholding for tax obligations - Stock Titan
Standard BioTools Inc. Revenue Breakdown – GETTEX:FLB - TradingView
Standard BioTools Inc (LAB) Income Statement - TradingKey
LAB|Standard BioTools Inc|Price:0.833|Chg%:-0.042 - TradingKey
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Standard BioTools Inc (LAB) Institutional Confidence - TradingKey
Standard BioTools Inc (LAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
LAB|Standard BioTools Inc|Price:0.802|Chg%:-0.031 - TradingKey
Standard BioTools Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Standard BioTools (NASDAQ: LAB) warned on Nasdaq minimum bid-price compliance - Stock Titan
Standard BioTools gets Nasdaq notice for failing $1 minimum bid price rule - Bitget
Standard BioTools Inc (LAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 - Investing News Network
Standard BioTools will post its next update after market close Aug. 5 - Stock Titan
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? - TradingView
Standard BioTools files merger registration with Treeline By Investing.com - Investing.com South Africa
Standard BioTools (LAB) details Treeline merger, $900M cash and TLN-121 data - Stock Titan
Standard BioTools files merger registration with Treeline - Investing.com
Standard BioTools Files S-4 for Merger with Treeline Biosciences, Highlighting Promising TLN-121 Clinical Data and Strong Cash Position - Quiver Quantitative
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction - GlobeNewswire
Standard BioTools (NASDAQ: LAB) outlines all-stock Treeline Biosciences merger and CVR plan - Stock Titan
Standard Biotools Inc (FLB) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
Standard BioTools (LAB) reports Q1 loss, tops revenue estimates - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB - Sahm
Standard BioTools (LAB) Rallies 4.4% After Support Test – Key Resistance in SightETF Creation Redemption - dars.gov.et
FLDM4094699 Bond Profile — Key Metrics - TradingView
FLDM4094699 Bond Redemption Profile - TradingView
Standard Biotools Inc (FLB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Standard Biotools Inc (FLB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Standard BioTools (LAB) Holds Above Key Support After Modest UptickBuffered ETF - dars.gov.et
Standard BioTools (LAB) Slides to $0.92 – Support Test in FocusInverse ETF Flow - dars.gov.et
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Standard BioTools (LAB) Surges Over 5%, Nears Key Resistance at $0.96RTH Profile - dars.gov.et
Standard BioTools Inc. (LAB) Surges 5% as Stock Approaches Key Resistance LevelOvernight Profile - dars.gov.et
Standard BioTools (LAB) Surges 5.36% as Shares Test Key Resistance LevelWave Truncation - dars.gov.et
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Turns Loss Estimate into ProfitEarnings Outlook Update - DonanımHaber
Standard BioTools Inc. (LAB) Q1 2026 Earnings: EPS Surges 800% Above Estimates, Stock Edges LowerWeak Earnings Momentum - dars.gov.et
Standard BioTools Inc. (LAB) Q1 2026 Earnings: EPS Surges 800% Above Estimates Amid Revenue Uncertainty - dars.gov.et
Enterprise value to revenue forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to earnings forward of Standard BioTools Inc. – BOATS:LAB - TradingView
Enterprise value to EBITDA forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to book forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to sales forward of Standard BioTools Inc. – BOATS:LAB - TradingView
Form 4 Standard Biotools Inc For: 23 June - Investing.com UK
Form 4 Standard Biotools Inc For: 23 June By Investing.com - Investing.com Australia
Standard BioTools (LAB) director receives new RSU and stock option awards - Stock Titan
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):